A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab

Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guedikian, Annie A., Randall, Megan E., Sharko, Anita, Leslie, William T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543311/
https://www.ncbi.nlm.nih.gov/pubmed/34720950
http://dx.doi.org/10.1159/000519181
_version_ 1784589613860388864
author Guedikian, Annie A.
Randall, Megan E.
Sharko, Anita
Leslie, William T.
author_facet Guedikian, Annie A.
Randall, Megan E.
Sharko, Anita
Leslie, William T.
author_sort Guedikian, Annie A.
collection PubMed
description Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-agent pembrolizumab for almost 3 years.
format Online
Article
Text
id pubmed-8543311
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-85433112021-10-29 A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab Guedikian, Annie A. Randall, Megan E. Sharko, Anita Leslie, William T. Case Rep Oncol Case Report Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-agent pembrolizumab for almost 3 years. S. Karger AG 2021-09-27 /pmc/articles/PMC8543311/ /pubmed/34720950 http://dx.doi.org/10.1159/000519181 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Guedikian, Annie A.
Randall, Megan E.
Sharko, Anita
Leslie, William T.
A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_full A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_fullStr A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_full_unstemmed A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_short A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
title_sort patient with metastatic microsatellite instability-high pancreatic ductal adenocarcinoma with a prolonged response to single-agent pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543311/
https://www.ncbi.nlm.nih.gov/pubmed/34720950
http://dx.doi.org/10.1159/000519181
work_keys_str_mv AT guedikiananniea apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT randallmegane apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT sharkoanita apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT lesliewilliamt apatientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT guedikiananniea patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT randallmegane patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT sharkoanita patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab
AT lesliewilliamt patientwithmetastaticmicrosatelliteinstabilityhighpancreaticductaladenocarcinomawithaprolongedresponsetosingleagentpembrolizumab

Ejemplares similares